Isofol Medical: Approaching AGENT read-out - DNB

In our view, the Q1 report was a non-event, with the results broadly in line with our estimates. The company continued its dialogue with the FDA and has started analysis of the pivotal AGENT study; it reiterated that top-line data is set to be presented within 2–3 months. Overall, the company looks to have been on track in the quarter. We largely maintain our forecasts and assumptions as well as our fair value of SEK14–26.

Länk till analysen i sin helhet: https://www.dnb.no/seg-fundamental/fundamentalweb/GetReportSpon.aspx?file=CMPSP_194678.pdf